Compare Amphastar Pharmaceuticals Inc (AMPH) vs Freshworks Inc (FRSH) Price & Performance

AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.

Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.

Freshworks (FRSH) trades at $11.66, down 2.67% on the day, as the stock consolidates near key technical levels. The company demonstrates strong fundamental improvement with 16% revenue growth in Q2 2026 and achieving GAAP profitability for the first time this year. Recent positive developments include FedRAMP certification progress and Gartner leadership recognition, while analyst sentiment remains evenly split between Buy and Hold ratings with a $16.50 consensus price target representing significant upside potential.

The outlook appears favorable given Freshworks' transition to profitability, expanding AI capabilities, and strong EX business growth. Key risks include competitive pressures in the SaaS sector and the need to maintain recent momentum. With attractive valuation metrics and positive cash flow trends, the stock presents a compelling opportunity for investors seeking exposure to the growing service operations software market.